Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study

Dig Liver Dis. 2018 Nov;50(11):1251-1255. doi: 10.1016/j.dld.2018.08.015. Epub 2018 Aug 21.

Authors

Céline Gregoire¹, Alexandra Briquet², Caroline Pirenne³, Chantal Lechanteur², Edouard Louis³, Yves Beguin⁴

Affiliations

¹ Department of Hematology, CHU of Liège, Liège, Belgium. Electronic address: celine.gregoire@chuliege.be.
² Laboratory of Cell and Gene Therapy (LTCG), CHU of Liège, Liège, Belgium.
³ Department of Gastro-Enterology, CHU of Liège, Liège, Belgium.
⁴ Department of Hematology, CHU of Liège, Liège, Belgium; Laboratory of Cell and Gene Therapy (LTCG), CHU of Liège, Liège, Belgium.

PMID: 30195816
DOI: 10.1016/j.dld.2018.08.015

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter

MeSH terms

Adult
Belgium
C-Reactive Protein / analysis
Crohn Disease / therapy*
Female
Humans
Leukocyte L1 Antigen Complex / analysis
Logistic Models
Lymphocyte Count
Male
Mesenchymal Stem Cell Transplantation*
Middle Aged
Pilot Projects
Recurrence
Severity of Illness Index
Young Adult

Substances

Leukocyte L1 Antigen Complex
C-Reactive Protein